Edit
Adaptive Biotechnologies Corp.
https://www.adaptivebiotech.com/Last activity: 17.05.2024
Active
Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
Community Guidelines and Terms of Use
The below guidelines are intended for use on our Facebook page. It applies to our Adaptive Biotechnologies community as well as any paid social advertising that is being run through the Adaptive corporate Facebook Ads Manager.
This is the official Facebook page for Adaptive Biotechnologies. It is intended to provide a forum for patients, caregivers, advocates, customers, and those who want to learn more about Adaptive, our products and services. We encourage you to participate and share your thoughts. Because we work in a heavily regulated industry, we want to make sure that all discussion stays on topic and is appropriate for the community.
In certain instances, your posts may not be published to our timeline or within any comment section associated with the Adaptive Biotechnologies profile based on the following guidelines. They may not be published if they:
Do not comply with Facebook’s Terms of Use.
- Include offensive language, inappropriate, racist, sexist or discriminatory remarks.
- Include disparaging remarks or personal attacks on other users.
- Share personal information, such as phone number, email address or home address.
- Share proprietary, confidential, sensitive, or nonpublic information.
- Promote products, offers, solicit money or attempt to recruit other community members.
- Violate any copyright or intellectual property.
- Request or offer advice on personal medical matters. Please consult your physician with any questions or concerns regarding personal matters of health and treatment.
- Contain a link without any context.
- Contain any information that is false or misleading.
- Perceived as disruptive, off topic, spam, and/or excessively repetitive.
Updates to this page are managed by Adaptive Biotechnologies. Please note that any content provided on the Adaptive Facebook page is for information purposes only and is not intended to be a substitute for medical advice from a healthcare professional. Always visit or talk to a qualified healthcare professional regarding any medical condition and questions about your health and treatments.
The Adaptive Facebook page contains comments posted by members of the public that/which do not reflect the views of Adaptive Biotechnologies. Adaptive Biotechnologies does not verify, approve, or endorse the comments or any information posted by visitors on this page, does not warrant their accuracy, and assumes no responsibility or liability arising from content of the page or for any error, omission, defamation, libel or slander. Caution should be used before relying on any statements or opinions expressed herein.
Please visit www.adaptivebiotech.com for information on Adaptive Biotechnologies’ operations, immune medicine platform, and business areas of focus.
We reserve the right to block users from this page who violate these Terms of Use. We reserve the right to remove this page and its contents at any time. Please check often for updates, as we reserve the right, at our sole discretion, to modify these Terms of Use, at any time. Your use of this Facebook page indicates your acceptance of the Terms of Use and any revisions to these terms.
Community Guidelines and Terms of Use
The below guidelines are intended for use on our Facebook page. It applies to our Adaptive Biotechnologies community as well as any paid social advertising that is being run through the Adaptive corporate Facebook Ads Manager.
This is the official Facebook page for Adaptive Biotechnologies. It is intended to provide a forum for patients, caregivers, advocates, customers, and those who want to learn more about Adaptive, our products and services. We encourage you to participate and share your thoughts. Because we work in a heavily regulated industry, we want to make sure that all discussion stays on topic and is appropriate for the community.
In certain instances, your posts may not be published to our timeline or within any comment section associated with the Adaptive Biotechnologies profile based on the following guidelines. They may not be published if they:
Do not comply with Facebook’s Terms of Use.
- Include offensive language, inappropriate, racist, sexist or discriminatory remarks.
- Include disparaging remarks or personal attacks on other users.
- Share personal information, such as phone number, email address or home address.
- Share proprietary, confidential, sensitive, or nonpublic information.
- Promote products, offers, solicit money or attempt to recruit other community members.
- Violate any copyright or intellectual property.
- Request or offer advice on personal medical matters. Please consult your physician with any questions or concerns regarding personal matters of health and treatment.
- Contain a link without any context.
- Contain any information that is false or misleading.
- Perceived as disruptive, off topic, spam, and/or excessively repetitive.
Updates to this page are managed by Adaptive Biotechnologies. Please note that any content provided on the Adaptive Facebook page is for information purposes only and is not intended to be a substitute for medical advice from a healthcare professional. Always visit or talk to a qualified healthcare professional regarding any medical condition and questions about your health and treatments.
The Adaptive Facebook page contains comments posted by members of the public that/which do not reflect the views of Adaptive Biotechnologies. Adaptive Biotechnologies does not verify, approve, or endorse the comments or any information posted by visitors on this page, does not warrant their accuracy, and assumes no responsibility or liability arising from content of the page or for any error, omission, defamation, libel or slander. Caution should be used before relying on any statements or opinions expressed herein.
Please visit www.adaptivebiotech.com for information on Adaptive Biotechnologies’ operations, immune medicine platform, and business areas of focus.
We reserve the right to block users from this page who violate these Terms of Use. We reserve the right to remove this page and its contents at any time. Please check often for updates, as we reserve the right, at our sole discretion, to modify these Terms of Use, at any time. Your use of this Facebook page indicates your acceptance of the Terms of Use and any revisions to these terms.
Location: United States, California, South San Francisco
Employees: 501-1000
Phone: +1 206-659-0067
Total raised: $550M
Founded date: 2009
Investors 5
Date | Name | Website |
- | RONA Holdi... | ronaholdin... |
- | Proioxis V... | proioxis.v... |
30.08.2023 | OrbiMed | orbimed.co... |
- | Illumina V... | illuminaVe... |
- | Sweetwater... | sweetwater... |
Funding Rounds 3
Date | Series | Amount | Investors |
12.09.2022 | - | $250M | - |
07.05.2015 | Series F | $195M | - |
07.04.2014 | Series C | $105M | - |
Mentions in press and media 33
Date | Title | Description |
17.05.2024 | Winners of 2024 Seattle ORBIE Awards Announced By SeattleCIO | Executives from GE Healthcare, Symetra Financial Corporation, Perkins Coie LLP, Eagleview Technologies, Adaptive Biotechnologies, and Electronic Arts Recognized for their Achievements. SEATTE, Wash., May 17, 2024 /PRNewswire-PRWeb/ -- Seatt... |
19.05.2023 | GeekWire Awards 2023 revealed: Community honors top innovation in Pacific Northwest tech | Jake Stallman, VP of build quality and design at Carbon Robotics, snags a selfie with R2-D2 while accepting the Hardware/Gadget/Robotics of the Year Award at the 2023 GeekWire Awards. (GeekWire Photo / Kevin Lisota) A Star Wars theme comple... |
11.04.2023 | Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more | Mark Adams. (Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory filing. Adams joined the Seattle-based biotech giant more than three years ago. The fi... |
01.02.2023 | Next-Generation Tools for Cell Therapy Characterization and Monitoring, Upcoming Webinar Hosted by Xtalks | Historically, tools that were developed for gene therapies have been repurposed for cell therapy monitoring; however, they have limitations including repeated validation requirements, limited assay sensitivity and suboptimal quantitative ac... |
08.12.2022 | Tech Moves: Ex-RealSelf leader joins Oggvo; ex-Adaptive CFO lands at Capella Space; and more | Maureen Ezekwugo. (Oggvo Photo) — Maureen Ezekwugo is now CEO of Oggvo, which develops customer review management software for small- to medium-sized businesses. Ezekwugo was previously at Seattle-based cosmetic treatment review platform Re... |
28.10.2022 | Optimizing Pre-Clinical Drug Development through Immune Receptor Sequencing in Mouse Models: Upcoming Webinar Hosted by Xtalks | TORONTO and SEATTLE (PRWEB) October 28, 2022 Attendees will learn about the basics of immune receptor profiling, as well as how immunosequencing can be applied to advance drug discovery and develop targeted therapies. The featured speaker w... |
12.09.2022 | Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million | SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and trea... |
12.09.2022 | Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million | - |
22.08.2022 | Seattle startup aiming to detect, treat Alzheimer’s and Parkinson’s disease raises cash | AltPep CEO and founder Valerie Daggett. (AltPep Photo) The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valeri... |
22.02.2022 | Used in the discovery of COVID-19 vaccines, genomics data analyses SaaS MiLaboratories raises $2.3 million | MiLaboratories, makers of MiXCR, a software suite that analyses genomics data to build a complete picture of immune response at the DNA level, has raised $2.3 million in a seed funding round. The capital will be used to develop a next-gener... |
Show more